Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenosylhomocysteinase pseudogene 3 (AHCYP3) is classified as a pseudogene of the adenosylhomocysteinase (AHCY) gene family. Pseudogenes are genomic DNA sequences similar to normal genes but are non-functional; they arise from duplication or retrotransposition events of their parent functional genes and typically do not code for an active protein. As a pseudogene, AHCYP3 does not encode a functional protein, does not possess known enzymatic, receptor, transporter, or therapeutic activity, and is not associated with recognized therapeutic targeting or disease roles. There is no current evidence that AHCYP3 (as opposed to its parental functional gene AHCY) is involved in drug interaction, disease pathology, therapeutic mechanisms, or biomarker status.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adenosylhomocysteinase pseudogene 3 (AHCYP3).